129 related articles for article (PubMed ID: 35081898)
1. Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.
Zhao X; Liu Y; Liu J; Qin J
Endocr Metab Immune Disord Drug Targets; 2022; 22(9):963-969. PubMed ID: 35081898
[TBL] [Abstract][Full Text] [Related]
2. Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats.
Zhao XY; Yu TT; Liu S; Liu YJ; Liu JJ; Qin J
World J Diabetes; 2020 Dec; 11(12):611-621. PubMed ID: 33384768
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
Guo T; Yan W; Cui X; Liu N; Wei X; Sun Y; Fan K; Liu J; Zhu Y; Wang Z; Zhang Y; Chen L
Mol Med; 2023 Sep; 29(1):132. PubMed ID: 37770820
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide improves pancreatic islet β cell apoptosis in rats with type 2 diabetes mellitus by inhibiting the IKKε/NF-κB pathway.
Liu YT; He T; Li HQ; Jiang P
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4818-4828. PubMed ID: 34337733
[TBL] [Abstract][Full Text] [Related]
5. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
[No Abstract] [Full Text] [Related]
6. Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway.
Fan L; Niu H; Zhao L; Yao R; He X; Lu B; Pang Z
Biomed Pharmacother; 2022 Apr; 148():112697. PubMed ID: 35176709
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
Zhang L; Wu X; Li X; Chang X; Ding X; Wang Q; Jiang T; Wang G; Liu J
Acta Diabetol; 2023 Jul; 60(7):971-979. PubMed ID: 37079136
[TBL] [Abstract][Full Text] [Related]
8. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
[TBL] [Abstract][Full Text] [Related]
9. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.
Xiao Y; Liu Y; Zhao L; Zhou Y
Metab Syndr Relat Disord; 2022 Oct; 20(8):459-465. PubMed ID: 35925752
[No Abstract] [Full Text] [Related]
10. Effect of Gegen Qinlian Decoction on Hepatic Gluconeogenesis in ZDF Rats with Type 2 Diabetes Mellitus Based on the Farnesol
Zhou Q; Song N; Wang SQ; Wang Y; Zhao YK; Zhu XD
Evid Based Complement Alternat Med; 2021; 2021():9922292. PubMed ID: 34422083
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
Xu X; Wang W; Lin L; Chen P
Tissue Cell; 2020 Oct; 66():101382. PubMed ID: 32933722
[TBL] [Abstract][Full Text] [Related]
12. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.
Yang J; Ao N; Du J; Wang X; He Y
Endocrine; 2015 May; 49(1):106-18. PubMed ID: 25471281
[TBL] [Abstract][Full Text] [Related]
14. Identification of Potential Therapeutic Targets and Pathways of Liraglutide Against Type 2 Diabetes Mellitus (T2DM) Based on Long Non-Coding RNA (lncRNA) Sequencing.
Huang Y; Li J; Chen S; Zhao S; Huang J; Zhou J; Xu Y
Med Sci Monit; 2020 Apr; 26():e922210. PubMed ID: 32238798
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
16. Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
Liu Y; Zhu D; Dong G; Zeng Y; Jiang P; Xiao Y
Adv Clin Exp Med; 2021 Feb; 30(2):157-163. PubMed ID: 33650330
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats.
Li J; Liu X; Fang Q; Ding M; Li C
Diabetol Metab Syndr; 2017; 9():94. PubMed ID: 29213335
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.
Ma H; Cui F; Dong JJ; You GP; Yang XJ; Lu HD; Huang YL
World J Gastroenterol; 2014 Oct; 20(40):14950-7. PubMed ID: 25356056
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
[TBL] [Abstract][Full Text] [Related]
20. [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
Ma ZZ; Ao N; Yang N; Yang J; Jin S; Du C; Du J
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):624-630. PubMed ID: 36038324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
